Compounded semaglutide and tirzepatide prices stay below brand self-pay in September index

A price index covering 14 telehealth providers recorded a median first-month price of $197 for compounded semaglutide and $299 for compounded tirzepatide as of September 3, 2026 ^[3]. Over roughly the same days, the Wegovy pen carried self-pay prices of $199 to $349 and Zepbound $299 to $449, before any membership fee is added ^[3].

On the brand side, LillyDirect lists Zepbound (tirzepatide) self-pay at $299 a month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for 7.5 mg through 15 mg ^[1]. The $449 tier applies when a refill happens within 45 days; without that refill, regular prices are $499 for 7.5 mg and $699 for 10 mg, 12.5 mg and 15 mg ^[1]. Zepbound is sold at those same self-pay prices as a KwikPen and as a single-dose vial, with needles or syringes purchased separately ^[1]. Mounjaro, the same molecule approved for type 2 diabetes, is listed at $499 a month self-pay at every dose through LillyDirect ^[2].

Wegovy self-pay runs $199 for the first two fills for new patients through December 31, 2026, then $349; the 7.2 mg dose is $399 ^[3]. The Wegovy pill is priced at $149, $199 or $299 depending on dose ^[3].

Membership fees sit on top of those medication prices at some programs. Noom's brand-medication track was listed at $39 for the first month and then $129 a month, while WW Med+ was $25 a month for an introductory period and then $74 a month on a 12-month plan, with medication billed separately ^[3]. Noom also sells compounded tirzepatide at $149 for the first month and $299 after ^[3]. WW does not offer compounded GLP-1s at all, a step third-party reviewers date to May 2025 ^[3].

The compounded market's legal footing narrowed when the FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025 ^[3]. Hims closed compounded semaglutide to new patients on March 9, 2026, after a settlement with Novo Nordisk, according to a July 2026 third-party review ^[3]. Among the providers reviewed by CitedRx, Medvi received an FDA warning letter in February 2026, altRx's parent company Trinity Healthcare Supply received one in June 2026, and Henry Meds faces unresolved litigation from Eli Lilly over compounded-tirzepatide marketing ^[4]. Compounded products are not FDA-reviewed for safety, effectiveness or quality the way brand-name Wegovy or Zepbound are ^[4]. The FDA had logged 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026 ^[3].

Why it matters for patients

Most people paying cash for a GLP-1 are choosing between a compounded product at roughly $197 to $299 for the first month and a brand product at $299 to $449 plus any membership fee ^[3]. Those totals are not directly comparable: the trial evidence behind Wegovy and Zepbound was generated with the brand formulations, and no major GLP-1 trial tested a compounded version ^[4].

Insurance rarely resolves the choice. Only 19% of large employers covered weight-loss GLP-1s in 2025, according to KFF figures cited by Noom ^[3]. WeightWatchers states on its pricing page that the Zepbound KwikPen is not eligible for insurance coverage ^[3], while Lilly's own LillyDirect page for that KwikPen says select insurance is accepted ^[1]. Medicare Part D beneficiaries with a prescription for weight management can access Zepbound through the Medicare GLP-1 Bridge at $50 a month, with prior authorization, from July 1, 2026 through December 31, 2027 ^[3].

What happens next

WW's $25 introductory membership rate was set to end September 8, 2026, at 11:59 p.m. PDT ^[3]. Wegovy's $199 introductory pen pricing for new patients runs through December 31, 2026 ^[3]. The Medicare GLP-1 Bridge program runs through December 31, 2027 ^[3].

Whether the branded-versus-compounded price gap narrows has not been reported. Provider menus, regulatory status and prices change frequently, and the figures above reflect pages read on September 3, 4 and 5, 2026 ^[3][4].